A5029390153- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Sarcoma Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Testicular diseases and treatments
- PARP inhibition in cancer therapy
- Pancreatic and Hepatic Oncology Research
- Cancer-related gene regulation
- RNA Interference and Gene Delivery
- Cancer, Lipids, and Metabolism
- Vascular Tumors and Angiosarcomas
- Adrenal and Paraganglionic Tumors
- Cardiac tumors and thrombi
- Neuroblastoma Research and Treatments
- Colorectal Cancer Screening and Detection
- Neurobiology and Insect Physiology Research
- Adenosine and Purinergic Signaling
- Renal and related cancers
- Economic and Financial Impacts of Cancer
The University of Texas MD Anderson Cancer Center
2025
Texas A&M University
2024-2025
Bryan College
2024
University of California, Los Angeles
2021-2023
University of Michigan
2023
Oregon Health & Science University
2017-2020
UCLA Health
2020
Ronald Reagan UCLA Medical Center
2020
Rainbow Babies & Children's Hospital
2016
Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination (HRR) such as
Significance The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for men with metastatic castration-resistant prostate cancer. However, not all patients respond, and de novo resistance mechanisms are largely unknown. To clarify that contribute to resistance, we conducted a single-arm clinical trial. Metastatic tissue biopsies were required prior study entry so could attempt identify molecular features associated resistance. Transcriptional profiling...
Osteosarcoma is the most common primary bone malignancy in teenagers and continues to confer a generally poor prognosis due its highly metastatic potential. Poor solubility water instability of curcumin limits bioavailability for use adjuvant situation improve long-term survival patients with osteosarcoma. To further obtain information regarding apoptosis induced by new analog, GO-Y078, human osteosarcoma cells, flow cytometric analysis, annexin V-FITC/PI staining assay, array, Western...
Higher neutrophil-derived cytokine lipocalin-2 (LCN2) expression possesses a versatile role in myriad of cancers, but little is known about the LCN2 on osteosarcoma metastasis. In this study, we demonstrated that higher inhibited cellular motility, migration, and invasion cells. Moreover, using RNA sequencing technology, found repressed MET gene U2OS Manipulation levels influenced migratory potential cells as migration was enhanced by transfecting with vectors containing constitutively...
Background Germline variants in fumarate hydratase ( FH ) are associated with autosomal dominant (AD) hereditary leiomyomatosis and renal cell cancer (HLRCC) recessive (AR) fumarase deficiency (FMRD). The prevalence penetrance across different remain unclear. Methods A database containing 120,061 records from individuals undergoing germline testing was obtained. were classified into 3 categories: AD HLRCC variants, AR FMRD of unknown significance (VUSs). Individuals these categories compared...
The purpose of this study was to measure genomic changes that emerge with enzalutamide treatment using analyses whole-genome sequencing and RNA sequencing.
ObjectiveTo clarify the link between germline variants in fumarate hydratase (FH), hereditary leiomyomatosis and renal cell cancer (HLRCC), paraganglioma (PGL) pheochromocytoma (PCC) we utilize a well-annotated testing database.MethodsRecords of 120,061 patients receiving were obtained. FH classified into 4 categories: autosomal dominant (AD) HLRCC variants, recessive (AR) fumarase deficiency (FMRD), previously reported as PGL/PCC unknown significance (VUS) not associated with (NPP-VUS)....
Abstract Background Vincristine, doxorubicin, and cyclophosphamide (VDC) alternating with ifosfamide etoposide (IE) administered every 2 weeks demonstrated a superior event-free survival compared 3-week dosing in landmark pediatric trial is now standard of care for younger patients. Only 12% patients enrolled that were over 18 years age; thus, the feasibility interval-compressed VDC/IE adults remains poorly described. We conducted retrospective analysis our institutional experience using...
Background: PARP inhibition is a promising therapeutic strategy for the treatment of men with metastatic castration-resistant prostate cancer whose tumors harbor homologous recombination DNA repair gene alterations. However, questions remain many practicing clinicians about which patients are ideally suited inhibitor treatment. This report details our institutional experience using therapy in harbored specific Patients and Methods: We performed retrospective chart review to identify at...
e14706 Background: Stem cell transplantation (SCT) and immune checkpoint inhibitors (ICIs) are both used to treat hematological malignancies. There may sometimes be an overlap in the patient’s exposure treatments. Theoretically, ICIs potentiate graft-versus-tumor effect following SCT but increase risk of inflammatory adverse events (AEs). Conversely, immunosuppression decrease immune-mediated AEs. We aim explore immunotherapy on severity AEs SCT. Methods: performed a single-center,...